HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Intratumoral Injection of HP007 Injection as Monotherapy in Patients With Relapsed or Refractory Advanced Solid Tumors, and to Explore the Preliminary Efficacy of HP007
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Niannian Wang, Project Manager
- 电话号码:+86 13161547878
- 邮箱:niannian_wang@junshipharma.com
学习地点
-
-
Jilin
-
Changchun、Jilin、中国、130000
- 招聘中
- The First Hospital of Jilin University
-
接触:
- Yanhua Ding, Chief Physician
- 邮箱:dingyanh@jlu.edu.cn
-
首席研究员:
- Yanhua Ding, Chief Physician
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male/female, 18-75 years inclusive.
- Histologically-confirmed unresectable advanced tumors (breast cancer, HNSCC, cutaneous melanoma, prostate cancer, HCC, etc.);
- no effective standard therapy or disease relapse/metastasis post-standard-of-care.
- ECOG PS 0-1;
- expected survival ≥3 months.
- At least 1 measurable lesion by RECIST 1.1. Lesion in prior radiation field must have confirmed progression ≥4 weeks post-radiation. Prostate cancer subjects must meet PCWG3 progression criteria.
- At least one lesion suitable for repeated intratumoral injection.
- Adequate hematopoietic and organ function:
- Males and females of child-bearing potential agree effective contraception from ICF signature to 3 months after last dose.
- Voluntarily sign ICF and comply with study procedures.
Exclusion Criteria:
-
Past/current medical conditions
- CNS or leptomeningeal metastasis.
- Residual toxicity from prior anti-tumor therapy >Grade 1 (CTCAE 6.0), except alopecia and Grade 2 peripheral neuropathy without safety risk.
- Poorly controlled pleural / ascitic / pericardial effusion requiring local intervention or repeated drainage.
- Active autoimmune disease or high-risk history of recurrence; organ transplant with immunosuppression.
- Interstitial lung disease / non-infectious pneumonitis; pulmonary embolism within prior 12 weeks.
- Severe cardio-cerebrovascular events within 6 months; QTcF ≥470 msec; LVEF ≤50%; NYHA ≥III heart failure; history of long-QT syndrome or ongoing QTc-prolonging drugs.
- Uncontrolled hypertension (SBP>160 mmHg and/or DBP>100 mmHg) or other uncontrolled systemic diseases.
- High bleeding risk / coagulation disorders: inherited/acquired bleeding-thrombotic predisposition; major bleeding within 3 months; thrombolytics within 10 days; ongoing anticoagulant/antiplatelet therapy (except heparin for CVC patency).
- Immunodeficiency; history of solid-organ or hematopoietic stem-cell transplantation.
- Active TB within past 5 years.
- Severe infection / trauma / GI perforation / fistula / tumor vascular invasion / bowel obstruction within 4 weeks; active infection or antibiotic use within prior 2 weeks (prophylaxis allowed); unexplained fever >38.5 ℃ (tumor-related fever may be allowed per Investigator judgment).
- Other active malignancy within 3 years, except: cervical carcinoma in-situ, local basal-cell carcinoma, or malignancies cured ≥5 years without recurrence.
-
Prior medications & treatments
- Local radiotherapy completed <1 week before first dose; >30% bone-marrow / extensive-field radiotherapy completed <4 weeks before first dose.
- Anti-tumor therapy within 4 weeks or less than 5 half-lives (whichever shorter).
- Systemic corticosteroids (>10 mg prednisone equivalent/day) or other immunosuppressants within 14 days.
- Prior immunotherapy with irAEs ≥Grade 3.
- Prior systemic TLR-agonist treatment (topical TLR agonists e.g. imiquimod permitted).
- Vaccination within 1 month prior to enrolment.
-
Allergy, general status & others
- Severe hypersensitivity (CTCAE 6.0 ≥Grade 3) to any investigational product component.
- Active HBV / HCV, positive syphilis or HIV serology.
- Participated in another interventional clinical trial within 4 weeks.
- Major surgery within 4 weeks before screening or planned major surgery during study.
- Alcohol / illicit-drug / substance abuse within 12 months.
- Documented neurological/psychiatric disorders leading to poor compliance.
- Pregnant or lactating females.
- Subjects judged unsuitable by the Investigator for any other reason.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HP007
Participate will recepit HP007 monotherpy with 4 dose groups |
Participate will recepit HP007 monotherpy with 4 dose groups |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
DLT
大体时间:up to one year
|
Safety endpoints: incidence and severity of DLT |
up to one year
|
|
AE
大体时间:up to two years
|
Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
SAE
大体时间:up to two years
|
Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
MTD
大体时间:up to one year
|
Maximum tolerated dose (MTD) |
up to one year
|
|
RP2D
大体时间:up to one year
|
Recommended dose for phase II trial |
up to one year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ORR
大体时间:up to two years
|
Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DOR
大体时间:up to two years
|
Efficacy endpoints: Duration of response (DOR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DCR
大体时间:up to two years
|
Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
PFS
大体时间:up to two years
|
Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
OS
大体时间:up to two years
|
Efficacy endpoints: Overall survival (OS) |
up to two years
|
|
Peak concentration(Cmax)
大体时间:up to two years
|
The pharmacokinetic parameters of WJ47156:peak concentration (Cmax) |
up to two years
|
|
the time to receive Cmax(Tmax)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007:the time to receive Cmax (Tmax) |
up to two years
|
|
Area Under the plasma concentration-time curve (AUC0-t, AUC0-∞)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007 :area under the plasma concentration-time curve (AUC0-t, AUC0-∞) |
up to two years
|
|
Volume of distribution (Vd)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007 :Volume of distribution (Vd) |
up to two years
|
|
Rate of clearance (C)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007 :Rate of clearance (CL) |
up to two years
|
|
Terminal half-life (t1/2)
大体时间:up to two years
|
The pharmacokinetic parameters of WJ47156 :terminal half-life (t1/2), |
up to two years
|
|
Steady-state peak concentration(Cmax,ss)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007 :steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Plasma trough concentration at steady state(Cmin,ss)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007:Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Accumulation ratio for AUC
大体时间:up to two years
|
The pharmacokinetic parameters of HP007:Accumulation ratio of area-under-the-curve, defined as steady-state AUC within one dosing interval divided by Day 1 AUC (typically AUC₀-₂₄h). It characterizes overall systemic exposure accumulation over the dosing cycle, used for efficacy and total exposure assessment. |
up to two years
|
|
the time to receive Cmax at steady state(Tmax,ss)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007 :the time to receive Cmax at steady state(Tmax,ss)for the main PK parameters for multiple dose) |
up to two years
|
|
Area Under the plasma concentration-time curve at steady state (AUC0-t, ss)
大体时间:up to two years
|
The pharmacokinetic parameters of HP007:area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose) |
up to two years
|
|
ADA
大体时间:up to two years
|
The incidence and changes of anti-drug antibody (ADA) after treatment were observed |
up to two years
|
|
Nab
大体时间:up to two years
|
The incidence and changes of neutralizing antibody (Nab) after treatment were observed |
up to two years
|
|
Cytokines
大体时间:up to one year
|
The changes of serum cytokines (IFN-α, IFN-γ, IL-6, IL-10, and chemokines IFN-γ-inducible protein 10 (IP-10) and TNF-α )in peripheral blood before and after treatment were observed |
up to one year
|
|
Subtype of lymphocyte
大体时间:up to one year
|
Flow cytometry was used to detect the changes in lymphocyte subsets in peripheral blood before and after treatment |
up to one year
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HP007CH101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.